MXCT MaxCyte Inc
Price (delayed)
$2.76
Market cap
$292.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.39
Enterprise value
$282.79M
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to
Highlights
MXCT's quick ratio is up by 12% since the previous quarter and by 3.5% year-on-year
MXCT's debt is down by 3.8% YoY
The company's gross profit fell by 20% QoQ and by 14% YoY
The revenue has declined by 15% since the previous quarter and by 6% year-on-year
Key stats
What are the main financial stats of MXCT
Market
Valuations
Earnings
Shares outstanding
106.03M
Market cap
$292.64M
Enterprise value
$282.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.41
Price to sales (P/S)
7.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.32
Revenue
$38.63M
Gross profit
$31.53M
Operating income
-$51.2M
Net income
-$41.06M
EBIT
-$41.06M
EBITDA
-$36.27M
Free cash flow
-$29.26M
Per share
Balance sheet
Liquidity
EPS
-$0.39
EPS diluted
-$0.39
Free cash flow per share
-$0.28
Book value per share
$1.96
Revenue per share
$0.37
TBVPS
$2.28
Total assets
$239.47M
Total liabilities
$33.22M
Debt
$18.03M
Equity
$206.25M
Working capital
$155.91M
Debt to equity
0.09
Current ratio
10.88
Quick ratio
10.09
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
-93.9%
Gross margin
81.6%
Net margin
-106.3%
Operating margin
-132.5%
Return on assets
-16.5%
Return on equity
-18.9%
Return on invested capital
-18.5%
Return on capital employed
-18.4%
Return on sales
-106.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MXCT stock price
How has the MaxCyte stock price performed over time
Intraday
1.85%
1 week
-0.72%
1 month
-17.37%
1 year
-32.85%
YTD
-33.65%
QTD
1.1%
Financial performance
How have MaxCyte's revenue and profit performed over time
Revenue
$38.63M
Gross profit
$31.53M
Operating income
-$51.2M
Net income
-$41.06M
Gross margin
81.6%
Net margin
-106.3%
MXCT's net margin is down by 36% from the previous quarter and by 16% YoY
MXCT's operating margin is down by 30% QoQ and by 13% YoY
The company's gross profit fell by 20% QoQ and by 14% YoY
The revenue has declined by 15% since the previous quarter and by 6% year-on-year
Growth
What is MaxCyte's growth rate over time
Valuation
What is MaxCyte stock price valuation
P/E
N/A
P/B
1.41
P/S
7.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.32
The EPS has contracted by 15% from the previous quarter and by 5% YoY
MXCT's P/B is 31% below its last 4 quarters average of 2.0
The equity has contracted by 11% YoY and by 3.3% from the previous quarter
MXCT's price to sales (P/S) is 25% less than its last 4 quarters average of 9.8
The revenue has declined by 15% since the previous quarter and by 6% year-on-year
Efficiency
How efficient is MaxCyte business performance
The ROS has contracted by 36% from the previous quarter and by 16% YoY
The return on equity has declined by 19% year-on-year and by 18% since the previous quarter
The ROA has contracted by 19% from the previous quarter and by 19% YoY
The ROIC has decreased by 16% from the previous quarter and by 10% YoY
Dividends
What is MXCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MXCT.
Financial health
How did MaxCyte financials performed over time
MXCT's quick ratio is up by 12% since the previous quarter and by 3.5% year-on-year
MXCT's total assets is down by 11% year-on-year and by 3.7% since the previous quarter
MXCT's debt is 91% less than its equity
MaxCyte's debt to equity has increased by 13% YoY
The equity has contracted by 11% YoY and by 3.3% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.